文献速递前列腺增生与排尿功能障碍

建模研究:安慰剂与药物治疗对前列腺增大进展风险男性储尿、排尿症状、夜尿症及生活质量的影响

Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-10-04

该建模研究利用CombAT研究和度他雄胺III期单药研究数据,采用广义最小二乘模型预测不同治疗下IPSS总分、储尿/排尿/夜尿评分、生活质量(IPSS Q8)及BPH影响指数(BII)的变化。结果显示多数患者特征下联合治疗预测获益大于任一单药,PVR及对应子评分等为显著预测因子,结果可通过交互式网络工具可视化。

要点

  • 联合治疗对五项结局的预测获益在多数患者特征下大于度他雄胺或坦索罗辛单药。
  • PVR及对应子评分是储尿和排尿子评分变化的显著预测因子。
  • PVR、年龄、Qmax和夜尿评分为夜尿变化的显著预测因子。

核心结论

  • 该预测建模研究有助于理解疾病进展危险因素如何相互作用并影响不同症状类型及生活质量评分的治疗效应。

研究设计与样本

  • 建模研究,使用CombAT研究数据预测活性治疗(度他雄胺、坦索罗辛、联合治疗)结局,使用度他雄胺III期单药研究数据预测安慰剂结局。
  • 采用广义最小二乘模型预测每项结局,预测因子包括年龄、IPSS总分/储尿/排尿/夜尿/生活质量(IPSS Q8)评分、BII、前列腺体积、Qmax、前列腺特异性抗原、PVR及12个月内α受体阻滞剂使用。
  • 结果通过交互式网络工具(www.bphtool.com)可视化。

主要发现

  • 在CombAT纳入标准内的大多数患者特征中,联合治疗对全部五项结局的预测获益大于任一单药治疗。
  • PVR及对应子评分是储尿和排尿子评分变化的显著预测因子;12个月内α受体阻滞剂使用、年龄(储尿子评分)和Qmax(排尿子评分)也是显著预测因子。
  • PVR、年龄、Qmax和夜尿评分是夜尿变化的显著预测因子。
  • PVR、Qmax、既往α受体阻滞剂使用、IPSS总分和生活质量(IPSS Q8)评分是生活质量(IPSS Q8)评分变化的显著预测因子。
  • BII的显著预测因子为PVR、年龄、IPSS总分和BII评分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Modeling studies using large datasets from men with lower urinary tract symptoms/benign prostate enlargement (LUTS/BPE) can predict changes in International Prostate Symptom Score (IPSS) and risk of acute urinary retention/surgery under different treatment regimens and according to predictors (baseline characteristics) that commonly define risk of progression. We assessed the impact of treatments on different symptom types (storage, voiding, and nocturia), quality of life (QoL; IPSS Q8), and BPH Impact Index [BII]). METHODS: Generalized least squares models were used to predict each outcome. Data from the CombAT study were used to predict outcomes for active treatments (dutasteride, tamsulosin, combination therapy). Predictors included: age; IPSS total, storage, voiding, nocturia and QoL (IPSS Q8) scores; BII; prostate volume; maximum urine flow rate (Qmax), prostate-specific antigen, postvoid residual urine (PVR); alpha-blocker usage within 12 months. Data from phase III dutasteride monotherapy studies were used to predict placebo outcomes. Results were visualized using an interactive web-based tool ( www.bphtool.com ). RESULTS: Combination therapy provided greater predicted benefit than either monotherapy for all five outcomes for most patient profiles within the CombAT inclusion criteria. PVR and corresponding subscores were significant predictors of change in both storage and voiding subscores. Alpha-blocker use within 12 months, age (storage subscore), and Qmax (voiding subscore) were also significant predictors. PVR, age, Qmax, and nocturia score were significant predictors of change in nocturia. PVR, Qmax, previous alpha-blocker use, total IPSS, and QoL (IPSS Q8) score were significant predictors of change in QoL (IPSS Q8) score. For BII, significant predictors were PVR, age, total IPSS, and BII score. The multivariable effect of covariates and treatments is best visualized through the interactive web-based tool. CONCLUSIONS: This predictive modeling study informs our understanding of how risk factors for disease progression interact and affect treatment impact on different symptom types and QoL scores.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Gravas S, Manuel-Palacios J, Chavan C, et al. Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression. Prostate Cancer Prostatic Dis. 2023. PMID: 37794168. doi:10.1038/s41391-023-00731-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。